or search on
|Title:||Opportunities and challenges for implementation of cost-effective lung cancer screening|
|Authors:||Weber MF; Wade SL; Canfell K|
|Categories:||Cancer Type - Lung Cancer|
|Journal Title:||DI Europe|
|Abstract:||In this article, we summarize the findings of our recent cost-effectiveness evaluation of lung cancer screening with low-dose computed tomography (LDCT)  in which we applied Australian health services costs and populationbased survival data to the outcomes observed in the U.S. National Lung Screening Trial (NLST)  and assessed the impact of a range of screening scenarios on incremental cost effectiveness ratios (ICER) . Our base case estimate was A$138,000 (± €87,000) per life-year gained and $233,000 (± €146,000) per quality-adjusted life year (QALY) gained. Compared to an indicative willingnessto-pay threshold of A$30,000-50,000 (± €19,000 - € 31,500) lung screening is not yet likely to be cost-effective in Australia. Variation in base-case parameters resulted in ICER estimations that ranged from A$127,000 to A$509,000 (± €80,000 to €320,000) per QALY gained.|
|Division:||Cancer Research Division|
|Funding Body:||KC was supported by a NHMRC Career Development Fellowship|
|Appears in Collections:||Research Articles|
Files in This Item:
There are no files associated with this item.
Items in DSpace are protected by copyright, with all rights reserved, unless otherwise indicated.